Daily close, T-120 (11/1/24) through T+5. Run-up high $59.42 on 3/7/25, low $45.89 on 12/24/24 (T-120 to T-1). FDA decision 4/18/25. Historical price action, not a forecast.
Positioning before the decision
On Apr 4, 2025, 14 days before the decision date, at-the-money options priced a move of ±10.8% through May 16, 2025 (the first listed expiry after the decision; ATM implied volatility 40%). The stock closed +0.1% at the first close across the decision and +2.8% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Yes. The FDA approved the application for Dupixent (dupilumab) on April 18, 2025. The primary source is linked on this page.
What was Dupixent (dupilumab) under FDA review for?
The application covered Chronic spontaneous urticaria (CSU). The FDA approved the application on April 18, 2025.
How did SNY stock react to the FDA decision?
On the decision day SNY moved +0.1%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.